Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19

Barbosa, Alexandre Naime; Silvinato, Antonio; Bacha, Hélio; Floriano, Idevaldo; Tanni, Suzana; Bernardo, Wanderley.

Rev. Assoc. Med. Bras. (1992, Impr.); 68 (1), 2022

Publication year: 2022

Anticuerpos Monoclonales Humanizados, Antirreumáticos, Azetidinas, COVID-19/tratamiento farmacológico, Piperidinas, Purinas, Pirazoles, Pirimidinas, SARS-CoV-2, Sulfonamidas

Fulltext

More related